Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A scheme for a dose-escalation study when the event is lagged.

J Hüsing1, W Sauerwein, K Hideghéty

  • 1Institut für Medizinische Informatik, Biometrie und Epidemiologie, Medizinische Einrichtungen der Universität-Gesamthochschule Essen, Hufelandstrasse 55, D-45127 Essen, Germany. johannes.huesing@uni-essen.de

Statistics in Medicine
|December 18, 2001
PubMed
Summary

This study introduces a new rule for clinical phase I trials to manage dose-limiting events (DLEs) that occur with a delay. This approach improves decision-making for patient accrual, potentially shortening study duration compared to standard methods.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Uveal melanoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up.

ESMO open·2026
Same author

30 years of ocular proton therapy, the Nice view.

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2022
Same author

Ocular proton therapy, pencil beam scanning high energy proton therapy or stereotactic radiotherapy for uveal melanoma; an in silico study.

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2022
Same author

[Factors Influencing Results of Mortality Measurement in the Corona Pandemic: Analyses of Mortality in Germany in 2020].

Gesundheitswesen (Bundesverband der Arzte des Offentlichen Gesundheitsdienstes (Germany))·2022
Same author

A model to identify individuals with a high probability of a SARS-CoV-2 infection.

The Journal of infection·2020
Same author

[Results of surgical and radiotherapeutic treatment of adenoid cystic carcinoma of the salivary glands].

HNO·2020

Area of Science:

  • Clinical Trials
  • Biostatistics
  • Pharmacology

Background:

  • Classical phase I trial designs assume immediate availability of dose-limiting event (DLE) data.
  • Delayed DLEs pose challenges for decision-making in ongoing trials.
  • Current designs may be insufficient when DLEs manifest after a lag period.

Purpose of the Study:

  • To propose a novel rule for individual patient accrual decisions in phase I trials with delayed DLEs.
  • To address the uncertainty in patient enrollment when DLE information is not immediately available.
  • To improve the efficiency of clinical phase I trials under specific DLE scenarios.

Main Methods:

  • Development of a new accrual rule for individual eligible patients.
  • Utilizing simulation studies to evaluate the proposed rule.

Related Experiment Videos

  • Comparison against the standard 'three-at-once' design.

    • Main Results:

    • The proposed rule provides a clear decision-making framework for patient accrual.
    • Simulation results demonstrate the effectiveness of the new rule.
    • The suggested approach shows an advantage in reducing overall study length compared to the 'three-at-once' design.

    Conclusions:

    • A new patient accrual rule is effective for phase I trials with delayed dose-limiting events.
    • This method enhances decision-making and potentially shortens trial duration.
    • The findings suggest an improvement over traditional trial designs in specific contexts.